Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ≥18 years old with type 1 or 2 diabetes mellitus with decreased BCVA due to center involving diabetic macular edema on spectral-domain optical coherence tomography.~2. Patients with central macular thickness CMT of ≥ 300 micrometers~Exclusion Criteria:~1. Ocular conditions that may affect macular perfusion (e.g. retinal vascular diseases, uveitis, vasculitis etc.)~2. History of vitreo-retinal surgeries.~3. Previous macular laser treatment~4. Presence of epi-retinal membrane involving the macula or vitreo-macular traction.~5. Media opacity preventing good image quality.~6. Uncontrolled glaucoma.~7. Thrombo-embolic events within 6 months~8. Previous intravitreal injections of anti-VEGF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab Group (Type: ACTIVE_COMPARATOR): Patients will receive monthly ranibizumab injections for 3 months.
- Bevacizumab Group (Type: ACTIVE_COMPARATOR): Patients will receive monthly bevacizumab injections for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).